Heron Therapeutics
Notice Regarding ZYNRELEF® with Vial Access Needle
Replacing ZYNRELEF with Vented Vial Spike
and Impact on 340B Virtual Inventory Management

On December 1, 2024 Heron Therapeutics ("Heron") launched new ZYNRELEF® covered outpatient drug products pursuant to a Food and Drug Administration-approved supplement to existing New Drug Application 211988. The new ZYNRELEF products are available in the same 400mg, 300mg, 200mg and 60mg strengths and identical to the existing ZYNRELEF formulations except for a different needle applicator. The vented vial spike has been replaced with a Vial Access Needle ("VAN"). Heron will be phasing out the prior versions of ZYNRELEF with the vented vial spike and selling only the ZYNRELEF formulations with the VAN going forward. Because each new formulation of ZYNRELEF represents the same covered outpatient drug product with the same 340B price, Heron will permit eligible 340B Covered Entities using a compliant 340B inventory replenishment model to count accumulations of each old National Drug Code ("NDC") of the ZYNRELEF strength toward replacement of equal quantities of each new NDC of the same ZYNRELEF strength as detailed in the crosswalk below:

Product	**Old NDC**	**New/Replacement NDC**
ZYNRELEF 400 mg/14mL, 12mg/14mL	47426-301-02	47426-501-02
ZYNRELEF 200mg/7mL, 6mg/7mL	47426-303-01	47426-503-01

If you have questions about this notice, please contact your distributor or Amanda Mikus, MBA, Sr. Director, Sales Operations and Business Intelligence at Heron Therapeutics at amikus@herontx.com.